tebentafusp sold brand name kimmtrak anticancer medication used treat uveal melanoma eye tebentafusp bispecific peptidehladirected cell tebentafusp given intravenous common side effects include cytokine release syndrome rash pyrexia fever pruritus itching fatigue tiredness nausea chills abdominal pain stomach pain edema swelling hypotension low blood pressure dry skin headache vomiting abnormal liver blood tebentafusp approved medical use united states january us food drug administration fda considers firstinclass tebentafusp indicated treatment adults unresectable metastatic uveal efficacy evaluated randomized openlabel multicenter trial participants metastatic uveal participants required genotype positive identified central participants excluded prior systemic therapy localized liverdirected therapy prior surgical resection oligometastatic disease participants clinically significant cardiac disease symptomatic untreated brain metastases two thirds participants treated tebentafusp one third participants treated comparator drugs based investigators choice included pembrolizumab ipilimumab benefit tebentafusp evaluated measuring long participants lived starting treatment tebentafusp compared participants received comparator trial conducted sites across countries including australia belgium canada france germany italy netherlands poland russian federation spain switzerland ukraine united kingdom united clinical trial used assess efficacy us food drug administration fda granted immunocores application tebentafusp priority review breakthrough therapy orphan drug february committee medicinal products human use chmp european medicines agency ema adopted positive opinion recommending granting marketing authorization medicinal product kimmtrak intended treatment uveal applicant medicinal product immunocore ireland tebentafusp approved medical use european union april httpsenwikipediaorgwikitebentafusp